Drug Modeling Software uses Microsoft® .NET framework.May 16, 2006 -
Web-based DMX Drug Model Explorer(TM) Web Server v1.5 allows clinical drug development teams to present and exchange complex information on modeled drug attributes, and to compare probable outcomes based on different treatment strategies, patient populations, and competing products. In addition to supporting Microsoft® SQL Server and Oracle®, software processes simulations created in SAS® XPORT transport format as well as S-PLUS® analysis software.
(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
Original Press release
Pharsight Corporation
321 E. Evelyn Ave, 3rd Fl.
Mountain View, CA, 94041-1530
USA
Pharsight Announces New DMX® Web Server Release Using Microsoft® .NET Framework
Modifications to Software Architecture Enhance Customer Deployment of Web Applications
MOUNTAIN VIEW, Calif., April 12 / -- Pharsight Corporation (BULLETIN BOARD: PHST) , a leading provider of software and strategic services for optimizing clinical drug development, today announced the release of Drug Model Explorer(TM) Web Server (DMX(R)) version 1.5. The new release will support increased compatibility with customer requirements for deployment of web applications and will allow future DMX releases to take advantage of .NET technologies.
DMX is a web-based tool that allows clinical drug development teams to present and exchange complex information on modeled drug attributes, and to efficiently compare probable outcomes based on different treatment strategies, patient populations and competing products.
DMX will continue to support Microsoft(R) SQL Server, a leading database product, and Oracle(R), the preferred database system in the pharmaceutical industry. DMX will also continue to process simulations created in SAS(R) XPORT transport format, a data exchange mechanism accepted by the Food and Drug Administration (FDA), as well as S-PLUS(R), a leading analysis software product.
"We continue to work closely with our customers to meet their changing and emerging technology needs," said Shawn M. O'Connor, President and Chief Executive Officer. "Enhancement of the DMX architecture using .NET technologies responds to our customers' drug development technology infrastructures and deployment requirements for enterprise web applications. In addition, enhancement of the DMX architecture will allow ongoing development activities to take advantage of component technologies for improved speed, security and integration with third party software. We believe we are illustrating our commitment to being responsive to our customers and to remaining at the forefront of technology development."
About DMX
DMX allows clinicians, biostatisticians, marketers, and other members of clinical development teams to quickly visualize the modeled efficacy, safety, and other performance attributes of a new drug versus competing therapies. Pharsight believes that DMX will help increase the usage of quantitative-based decision-making in the drug development process. DMX can enhance the entire development team's understanding of a drug's likely clinical potential and limitations, and enable more efficient decision-making by providing direct interaction with modeling results presented as a series of intuitive plots and tables.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com/ .
NOTE: Pharsight, DMX, and Drug Model Explorer are registered trademarks or trademarks of Pharsight Corporation.
All other brand and product names are trademarks or registered trademarks of their respective holders.
|
|
|
|
|
|
|
| 
